Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease

References

• BlesaRBallardCOrgogozoJM2007Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer diseaseNeurology694 Suppl 1S23817646620
   PubMed Web of Science ®Google Scholar
• Corey-BloomJAnandRVeachJA1998A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartate), a new acetylcholinesterase inhibitor in patients with mild to moderate severe Alzheimer`s diseaseInt J Geriatr Psychopharmacol15565
   Google Scholar
• CorriganJDHinkeldeyNS1987Relationships between parts A and B of the Trail Making TestJ Clin Psychol4340293611374
   PubMed Web of Science ®Google Scholar
• CrisbyMCarlsonLAWinbladB2002Statins in the prevention and treatment of Alzheimer diseaseAlzheimer Dis Assoc Disord16131612218642
   PubMed Web of Science ®Google Scholar
• CummingsJWinbladB2007A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementiaExpert Rev Neurother714576317997695
   PubMedGoogle Scholar
• CummingsJL2004Alzheimer’s diseaseN Engl J Med351566715229308
   PubMed Web of Science ®Google Scholar
• DarveshSWalshRKumarR2003Inhibition of human cholines-terases by drugs used to treat Alzheimer diseaseAlzheimer Dis Assoc Disord171172612794390
   PubMed Web of Science ®Google Scholar
• DewachterIVan LeuvenF2002Secretases as targets for the treatment of Alzheimer’s disease: the prospectsLancet Neurol14091612849363
   PubMed Web of Science ®Google Scholar
• DodartJCBalesKRGannonKS2002Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease modelNat Neurosci5452711941374
   PubMed Web of Science ®Google Scholar
• DodelRCHampelHDuY2003Immunotherapy for Alzheimer’s diseaseLancet Neurol22152012849209
   PubMed Web of Science ®Google Scholar
• FabbriniGBrotchieJMGrandasF2007Levodopa-induced dyskinesiasMov Disord22137989 quiz 52317427940
   PubMed Web of Science ®Google Scholar
• FarlowMAnandRMessinaJJr2000A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s diseaseEur Neurol442364111096224
   PubMed Web of Science ®Google Scholar
• FarlowMRCummingsJL2007Effective pharmacologic management of Alzheimer’s diseaseAm J Med1203889717466645
   PubMed Web of Science ®Google Scholar
• FolsteinMFFolsteinSEMcHughPR1975“Minimental state”. A practical method for grading the cognitive state of patients for the clinician”J Psychiatr Res12189981202204
   PubMed Web of Science ®Google Scholar
• GalaskoDBennettDSanoM1997An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative StudyAlzheimer Dis Assoc Disord11Suppl 2S3399236950
   PubMed Web of Science ®Google Scholar
• HardyJSelkoeDJ2002The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeuticsScience297353612130773
   PubMed Web of Science ®Google Scholar
• HossainMJheeSSShiovitzT2002Estimation of the absolute bio-availability of rivastigmine in patients with mild to moderate dementia of the Alzheimer’s typeClin Pharmacokinet412253411929322
   PubMed Web of Science ®Google Scholar
• in t’ VeldBARuitenbergAHofmanA2001Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s diseaseN Engl J Med34515152111794217
   PubMed Web of Science ®Google Scholar
• InglisF2002The tolerability and safety of cholinesterase inhibitors in the treatment of dementiaInt J Clin Pract Suppl127456312139367
   PubMedGoogle Scholar
• Institute for Quality and Efficiency in Health Care2007Cholinesterase inhibitors in Alzheimer’s disease
   Google Scholar
• JannMWShirleyKLSmallGW2002Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitorsClin Pharmacokinet417193912162759
   PubMed Web of Science ®Google Scholar
• LefevreGSedekGHuangHL2007Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site applicationJ Clin Pharmacol47471817389556
   PubMed Web of Science ®Google Scholar
• LefevreGSedekGJheeSS2008Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patientsClin Pharmacol Ther831061417522596
   PubMed Web of Science ®Google Scholar
• McGeerPLSchulzerMMcGeerEG1996Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studiesNeurology47425328757015
   PubMed Web of Science ®Google Scholar
• MercierFLefevreGHuangHL2007Rivastigmine exposure provided by a transdermal patch versus capsulesCurr Med Res Opin23319920418001519
   PubMed Web of Science ®Google Scholar
• MorganDDiamondDMGottschallPE2000A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s diseaseNature408982511140686
   PubMed Web of Science ®Google Scholar
• NICE2007Donezepil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease (amended)NICE technology appraisal guidance 111 (amended)
   Google Scholar
• Novartis2007 http://wwwpharmausnovartiscom/product/pi/pdf/exelonpatchpdf
   Google Scholar
• OertelWRossJSEggertK2007Rationale for transdermal drug administration in Alzheimer diseaseNeurology694 Suppl 1S4917646621
   PubMed Web of Science ®Google Scholar
• OrgogozoJMGilmanSDartiguesJF2003Subacute meningoen-cephalitis in a subset of patients with AD after Abeta42 immunizationNeurology611465412847155
   PubMed Web of Science ®Google Scholar
• PermanneBAdessiCFragaS2002Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer’s disease?J Neural Transm Suppl6229330112456072
   PubMedGoogle Scholar
• PerryEKTomlinsonBEBlessedG1978Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementiaBr Med J214579719462
   PubMed Web of Science ®Google Scholar
• PolinskyRJ1998Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s diseaseClin Ther20634479737824
   PubMed Web of Science ®Google Scholar
• PrianoLGascoMRMauroA2006Transdermal treatment options for neurological disorders: impact on the elderlyDrugs Aging233577516823990
   PubMed Web of Science ®Google Scholar
• PuglielliLTanziREKovacsDM2003Alzheimer’s disease: the cholesterol connectionNat Neurosci63455112658281
   PubMed Web of Science ®Google Scholar
• RaskindMAPeskindERTruyenL2004The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trialArch Neurol61252614967774
   PubMed Web of Science ®Google Scholar
• RosenWGMohsRCDavisKL1984A new rating scale for Alzheimer’s diseaseAm J Psychiatry1411356646496779
   PubMed Web of Science ®Google Scholar
• RoslerMAnandRCicin-SainA1999Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trialBmj318633810066203
   PubMed Web of Science ®Google Scholar
• ScarpiniEScheltensPFeldmanH2003Treatment of Alzheimer’s disease: current status and new perspectivesLancet Neurol25394712941576
   PubMed Web of Science ®Google Scholar
• SchenkDBarbourRDunnW1999Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouseNature400173710408445
   PubMed Web of Science ®Google Scholar
• SchneiderLSOlinJT1996Clinical global impressions in Alzheimer’s clinical trialsInt Psychogeriatr827788 discussion 88–908994897
   PubMedGoogle Scholar
• SchwabeUPaffrathD2007Arzneiverordnungs-Report 2007HeidelbergSpringer
   Google Scholar
• SmallGDuboisB2007A review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patchCurr Med Res Opin2327051317892635
   PubMed Web of Science ®Google Scholar
• SmallGWKauferDMendiondoMS2005Cognitive performance in Alzheimer’s disease patients receiving rivastigmine for up to 5 yearsInt J Clin Pract59473715853867
   PubMed Web of Science ®Google Scholar
• SotoCSaborioGPPermanneB2000Inhibiting the conversion of soluble amyloid-beta peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer’s disease therapyActa Neurol Scand Suppl17690511261811
   PubMedGoogle Scholar
• SummersWKMajovskiLVMarshGM1986Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer typeN Engl J Med315124152430180
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration2008 http://wwwfdagov/consumer/updates/exelonpatch080307html
   Google Scholar
• van GoolWAAisenPSEikelenboomP2003Anti-inflammatory therapy in Alzheimer’s disease: is hope still alive?J Neurol2507889212883918
   PubMed Web of Science ®Google Scholar
• WatsonYIArfkenCLBirgeSJ1993Clock completion: an objective screening test for dementiaJ Am Geriatr Soc411235408227899
   PubMed Web of Science ®Google Scholar
• WattsRLJankovicJWatersC2007Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson diseaseNeurology68272617202432
   PubMed Web of Science ®Google Scholar
• WeggenSEriksenJLDasP2001A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activityNature414212611700559
   PubMed Web of Science ®Google Scholar
• WinbladBCummingsJAndreasenN2007aA six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsuleInt J Geriatr Psychiatry224566717380489
   PubMed Web of Science ®Google Scholar
• WinbladBGrossbergGFrolichL2007bIDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer diseaseNeurology694 Suppl 1S142217646619
   PubMed Web of Science ®Google Scholar
• WinbladBKawataAKBeusterienKM2007cCaregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s diseaseInt J Geriatr Psychiatry224859117407176
   PubMed Web of Science ®Google Scholar
• XieWStribleyJAChatonnetA2000Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesteraseJ Pharmacol Exp Ther29389690210869390
   PubMed Web of Science ®Google Scholar
• YangLPKeatingGM2007Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer’s typeCNS Drugs219576517927299
   PubMed Web of Science ®Google Scholar